antineoplastic agent

Brand Name: Lenvenib 4 mg Capsule Active Ingredient: Lenvatinib (4 mg per capsule) – a multikinase inhibitor used in cancer therapy. Drug Class: Antineoplastic agent, tyrosine kinase inhibitor (TKI) that blocks proteins promoting tumor growth and blood vessel formation (angiogenesis). Dosage Form: Oral capsules. Strength: 4 mg lenvatinib per capsule. Primary Uses / Indications : Lenvenib 4 mg is used for treatment in adults of various advanced cancers, often when other treatments are not effective: Pharmacology & How It Works : Mechanism: Lenvatinib inhibits multiple receptor tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFR α, RET, and KIT — proteins that help tumors grow and form new blood vessels. It slows or stops cancer progression by cutting off oxygen/nutrient supply and reducing cancer cell growth Indications : Differentiated Thyroid Cancer (DTC) – especially if refractory to radioactive iodine. Hepatocellular Carcinoma (HCC) – unresectable liver cancer. Renal Cell Carcinoma (RCC) – advanced kidney cancer, often with other anticancer drugs (e.g., everolimus). Endometrial Carcinoma – advanced uterine cancer, frequently combined with immunotherapy (e.g., pembrolizumab). Dosage & Administration : Taken orally once daily, with or without food. Swallow capsules whole; do not crush, chew, or open. Dose adjustments are common based on side effects and patient’s condition — monitored by the treating physician. Main Medical Uses (Cancer Treatment) : Lenvenib 4 mg is an anticancer medicine used in adults for: Differentiated Thyroid Cancer (DTC) When cancer has spread or does not respond to radioactive iodine treatment. Hepatocellular Carcinoma (HCC) Unresectable (cannot be removed by surgery) liver cancer. Renal Cell Carcinoma (RCC) Advanced kidney cancer (often used with other cancer medicines). Endometrial Cancer Advanced uterine cancer, usually combined with immunotherapy (e.g., pembrolizumab). Lenvenib 4 mg capsule contains the active ingredient Lenvatinib, which is a receptor tyrosine kinase (RTK) inhibitor used as an anti-cancer medication to treat several types of advanced cancers. It works by blocking specific proteins that promote the growth of cancer cells and the development of new blood vessels that supply tumors, effectively starving them of nutrients. Primary Uses of Lenvenib 4 mg : Differentiated Thyroid Cancer (DTC): Used for the treatment of progressive or advanced thyroid cancer that is not responsive to radioactive iodine therapy. Hepatocellular Carcinoma (Liver Cancer): Used for the treatment of advanced or unresectable primary liver cancer. Renal Cell Carcinoma (Kidney Cancer): Used in combination with other medications (like everolimus or pembrolizumab) for advanced kidney cancer, particularly when previous treatments have failed. Endometrial Carcinoma (Uterine Cancer): Used in combination with pembrolizumab to treat advanced endometrial cancer that has progressed after prior treatment. How It Works : Lenvatinib is a tyrosine kinase inhibitor (TKI). It blocks proteins that: Help cancer cells grow Form new blood vessels (angiogenesis) By cutting off the tumor’s blood supply, it slows cancer growth.

Medicine Name: Nindanib 150 mg Soft Gelatin Capsule Form: Oral soft gelatin capsule Strength: 150 mg nintedanib per capsule (active ingredient) Composition : Active Ingredient: • Nintedanib 150 mg (as the primary active compound) — a tyrosine kinase inhibitor that targets multiple signalling pathways involved in fibrosis and tumour growth. Therapeutic Class : Class: Antifibrotic / Antineoplastic agent Action: Tyrosine kinase inhibition — blocks receptors like VEGF, FGF, and PDGF involved in fibrosis and cell proliferation pathways. Idiopathic Pulmonary Fibrosis (IPF): Treats this progressive, irreversible lung disease, helping to reduce the rate of lung capacity decline by 50%. Chronic Fibrosing Interstitial Lung Diseases (ILDs): Manages progressive lung diseases that cause scarring. Systemic Sclerosis-Associated ILD (SSc-ILD): Used to slow the rate of decline in lung function in patients with this specific condition. Non-Small Cell Lung Cancer (NSCLC): Used in combination with docetaxel to manage locally advanced, metastatic, or recurrent adenocarcinoma, typically after first-line chemotherapy has failed. Key Properties : Route of Administration: Oral (capsule to be swallowed whole) Storage: Store below ~25–30 °C, in a cool, dry place, protected from moisture and light. Typical Dosage: Often 150 mg twice daily with food (as prescribed by a doctor; dosage may vary based on condition). Nindanib 150 mg Capsule is a tyrosine kinase inhibitor primarily used to treat idiopathic pulmonary fibrosis (IPF) and other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype. It slows the decline of lung function by reducing scarring. It is also used in combination with docetaxel for certain non-small cell lung cancers. Nindanib contains nintedanib, an antifibrotic and anti-cancer medicine. It is mainly used to treat certain lung diseases and some cancers. Idiopathic Pulmonary Fibrosis (IPF) Slows the progression of lung scarring and helps preserve lung function. Other Chronic Fibrosing Interstitial Lung Diseases (ILDs) Used in progressive fibrosing lung conditions to reduce further lung damage. Systemic Sclerosis-associated ILD (SSc-ILD) Helps slow lung function decline in patients with scleroderma-related lung fibrosis.